+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Biomarker Market (2022-2027) by Biomarker Type, Biomolecule Type, Cancer Type, Profiling Technology, Application, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon


  • 186 Pages
  • April 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5601787
UP TO OFF until Dec 31st 2023
The Global Cancer Biomarker Market is estimated to be USD 16.14 Bn in 2022 and is projected to reach USD 29.92 Bn by 2027, growing at a CAGR of 13.14%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Cancer Biomarker Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Cancer Biomarker Market is segmented based on Biomarker Type, Biomolecule Type, Cancer Type, Profiling Technology, Application, and Geography.
  • By Biomarker Type, the market is classified into Protein Biomarkers and Genetic Biomarkers.
  • By Biomolecule Type, the market is classified into Epigenetic, Genetic, Metabolic and Proteomic.
  • By Cancer Type, the market is classified into Breast Cancer, Lung Cancer, Colorectal Cancer (CRC), Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin’S Lymphoma (NHL), Kidney Cancer, and Other Cancers.
  • By Profiling Technology, the market is classified into Omics Technology, Imaging Technologies, Immunoassays, Bioinformatics, and Cytogenetics.
  • By Application, the market is classified into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Other Applications.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Abbott, Agilent, Becton, Dickinson & Company, Biomerieux, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Cancer Biomarker Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The report analyses the Global Cancer Biomarker Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cancer Biomarker Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Cancer Biomarker Market

What is the estimated value of the Global Cancer Biomarker Market?

The Global Cancer Biomarker Market was estimated to be valued at $16.14 Billion in 2022.

What is the growth rate of the Global Cancer Biomarker Market?

The growth rate of the Global Cancer Biomarker Market is 13.1%, with an estimated value of $29.92 Billion by 2027.

What is the forecasted size of the Global Cancer Biomarker Market?

The Global Cancer Biomarker Market is estimated to be worth $29.92 Billion by 2027.

Who are the key companies in the Global Cancer Biomarker Market?

Key companies in the Global Cancer Biomarker Market include Abbott, Agilent, Becton, Dickinson & Company, Biomerieux, Bio, Rad, Biovision, Centogene, Danaher and GE Healthcare.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increase in Instances of Cancer and Higher Acceptance for Treatment
4.1.2 Growing R&D on Cancer Biomarkers
4.1.3 Increase Use of Cancer Biomarkers in Drug Discovery and Development
4.2 Restraints
4.2.1 Unfavourable Reimbursement Policies and Regulatory Framework
4.2.2 Technical Issues Related to mple Collection and Storage
4.3 Opportunities
4.3.1 Growing Demand for Personalized Medicines
4.3.2 Technology Advancement Coupled with the Research on Cancer Biomarkers
4.4 Challenges
4.4.1 Cancer Biomarker Validation
4.4.2 Shortage of Skilled Professionals
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Cancer Biomarker Market, By Biomarker Type
6.1 Introduction
6.2 Protein Biomarkers
6.3 Genetic Biomarkers
7 Global Cancer Biomarker Market, By Biomolecule Type
7.1 Introduction
7.2 Epigenetic
7.3 Genetic
7.4 Metabolic
7.5 Proteomic
8 Global Cancer Biomarker Market, By Cancer Type
8.1 Introduction
8.2 Breast Cancer
8.3 Lung Cancer
8.4 Colorectal Cancer (CRC)
8.5 Prostate Cancer
8.6 Melanoma
8.7 Leukemia
8.8 Thyroid Cancer
8.9 Bladder Cancer
8.10 Non-Hodgkin’S Lymphoma (NHL)
8.11 Kidney Cancer
8.12 Other Cancers
9 Global Cancer Biomarker Market, By Profiling Technology
9.1 Introduction
9.2 Omics Technology
9.2.1 Proteomics
9.2.2 Genomics Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR)
9.2.3 Other Omics Technologies
9.3 Imaging Technologies
9.3.1 Ultrasound Imaging
9.3.2 Computed Tomography (CT)
9.3.3 Magnetic Resonance Imaging (MRI)
9.3.4 Po
10 Global Cancer Biomarker Market, By Application
10.1 Introduction
10.2 Diagnostics
10.3 Research & Development
10.4 Prognostics
10.5 Risk Assessment
10.6 Other Applications
11 Global Cancer Biomarker Market, By
11.1 Introduction
12 Global Cancer Biomarker Market, By
12.1 Introduction
13 Americas’ Cancer Biomarker Market
13.1 Introduction
13.2 Argentina
13.3 Brazil
13.4 Canada
13.5 Chile
13.6 Colombia
13.7 Mexico
13.8 Peru
13.9 United States
13.10 Rest of Americas
14 Europe’s Cancer Biomarker Market
14.1 Introduction
14.2 Austria
14.3 Belgium
14.4 Denmark
14.5 Finland
14.6 France
14.7 Germany
14.8 Italy
14.9 Netherlands
14.10 Norway
14.11 Poland
14.12 Russia
14.13 Spain
14.14 Sweden
14.15 Switzerland
14.16 United Kingdom
14.17 Rest of Europe
15 Middle East and Africa’s Cancer Biomarker Market
15.1 Introduction
15.2 Egypt
15.3 Israel
15.4 Qatar
15.5 Saudi Arabia
15.6 South Africa
15.7 United Arab Emirates
15.8 Rest of MEA
16 APAC’s Cancer Biomarker Market
16.1 Introduction
16.2 Australia
16.3 Bangladesh
16.4 China
16.5 India
16.6 Indonesia
16.7 Japan
16.8 Malaysia
16.9 Philippines
16.10 Singapore
16.11 South Korea
16.12 Sri Lanka
16.13 Thailand
16.14 Taiwan
16.15 Rest of Asia-Pacific
17 Competitive Landscape
17.1 Competitive Quadrant
17.2 Market Share Analysis
17.3 Strategic Initiatives
17.3.1 M&A and Investments
17.3.2 Partnerships and Collaborations
17.3.3 Product Developments and Improvements
18 Company Profiles
18.1 Abbott
18.2 Agilent
18.3 Becton, Dickinson & Company
18.4 Biomerieux
18.5 Bio-Rad
18.6 Biovision
18.7 Centogene
18.8 Danaher
18.9 GE Healthcare
18.10 Hologic
18.11 Illumina
18.12 Invivoscribe
18.13 Merck & Co
18.14 Meso Scale Diagnostics
18.15 Myriad Genetics
18.16 Olink
18.17 Perkinelmer
18.18 Qiagen
18.19 Quest Diagnostics
18.20 Roche
18.21 Siemens Healthineers
18.22 Sysmex Corporation
18.23 Thermo Fisher Scientific
19 Appendix
19.1 Questionnaire

Companies Mentioned

  • Abbott
  • Agilent
  • Becton, Dickinson & Company
  • Biomerieux
  • Bio-Rad
  • Biovision
  • Centogene
  • Danaher
  • GE Healthcare
  • Hologic
  • Illumina
  • Invivoscribe
  • Merck & Co
  • Meso Scale Diagnostics
  • Myriad Genetics
  • Olink
  • Perkinelmer
  • Qiagen
  • Quest Diagnostics
  • Roche
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific